Table 1.
Demographic and clinical characteristics of patients with left ventricular systolic dysfunction and non-left ventricular systolic dysfunction
| Non-LVSD group (n = 73) |
LVSD group (n = 51) |
p | |
|---|---|---|---|
| Basic characteristic | |||
| Male sex—no. (%) | 49 (67.1%) | 37 (72.5%) | 0.519 |
| Age—year | 68 (63,74) | 68 (57,77) | 0.931 |
| BMI (kg/m2) | 24.1 (21.6,26.1) | 22.5 (20.1,25.2) | 0.061 |
| LV GLS (%) | 17.6 (18.2,19.6) | 15.9 (14.7,16.8) | < 0.001* |
| LV EF (%) | 52.1 ± 0.5 | 51.5 ± 0.8 | 0.057 |
| Septic shock—no. (%) | 54 (74.0%) | 39(76.5%) | 0.752 |
| Underlying medical conditions | |||
| Hypertension—no. (%) | 33 (45.2%) | 25 (49.0%) | 0.675 |
| Diabetes—no. (%) | 14 (19.2%) | 8 (15.7%) | 0.616 |
| Chronic kidney injury—no. (%) | 7 (9.6%) | 4 (7.8%) | 0.737 |
| Clinical characteristics | |||
| Respiratory rate (bpm) | 24 (20,29) | 22 (20,26) | 0.337 |
| Blood pressure (mmHg) | 67.3 (60.7,80) | 73 (63.3,85.7) | 0.217 |
| Heart rate (bpm) | 110.3 ± 24.0 | 112.0 ± 25.5 | 0.714 |
| Body temperature (℃) | 37.8 ± 0.1 | 37.6 ± 0.1 | 0.476 |
| CVP (mmHg) | 8.4 ± 3.8 | 9.9 ± 4.9 | 0.087 |
| Organ function score | |||
| APACHE II score | 16.0 (12,20) | 17 (14,22) | 0.352 |
| SOFA score | 9.6 ± 3.0 | 10.9 ± 3.4 | 0.027* |
| Laboratory data | |||
| Leucocyte count (109/L) | 11.2 (6.2,19.2) | 9.9 (6.0,17.5) | 0.575 |
| Hemoglobin (g/L) | 108.0 ± 27.1 | 105.3 ± 35.9 | 0.853 |
| Platelet (109/L) | 160 (104,215) | 134 (89,224) | 0.369 |
| Albumin (g/L) | 27.6(23.7,31.4) | 29.7(26.232.8) | 0.188 |
| Bilirubin (mmol/L) | 20.2 (12.5,30.9) | 18.8 (13.4,25.8) | 0.455 |
| Plasma creatinine (umol/L) | 90.3(62.8,173.5) | 110.2(65.1,178.9) | 0.542 |
| PCT (ng/mL) | 3.3 (0.5,21) | 22 (0.7,91) | 0.013 |
| Hs-TnI (ng/mL) | 0.04 (0.02,0.12) | 0.27 (0.07,0.86) | < 0.001 |
| NT-proBNP (pg/mL) | 1020 (321,3060) | 4560 (1740,9580) | < 0.001 |
| pH | 7.34 ± 0.09 | 7.32 ± 0.11 | 0.337 |
| Lac (mmol/L) | 2.5 (1.7, 3.8) | 3.7 (2.2, 5.9) | 0.008 |
| P(v-a)CO2 > 6 mmHg no. (%) | 27 (61.4%) | 22 (64.7%) | 0.762 |
| 24-h fluid balance (mL) | 1994.3 ± 159.6 | 1892.1 ± 237.9 | 0.711 |
| Vasoactive drugs | |||
| VDI (ug/min) | 18 (0,42) | 36 (12,60) | 0.007* |
| Inotropic drugs used—no. (%) | 2 (2.8%) | 4 (7.8%) | 0.193 |
| Site of infection—no. (%) | |||
| Lungs | 20 (27.4%) | 20 (39.2%) | 0.196 |
| Blood | 1 (1.4%) | 2 (3.9%) | |
| Abdomen | 45 (61.6%) | 21 (41.2%) | |
| Soft tissue | 2 (2.7%) | 3 (5.9%) | |
| Urinary tract | 2 (2.7%) | 2 (3.9%) | |
| Central nervous system | 2 (2.7%) | 0 | |
| Others | 1 (1.4%) | 3 (5.9%) | |
LVSD left ventricular systolic dysfunction, BMI body mass index, LV GLS left ventricular global longitudinal strain, LV EF left ventricular ejection fraction, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, PCT procalcitonin, Hs-TnI high sensitive troponin I, NT-proBNP N-terminal pro-brain natriuretic peptide, Lac lactate, CVP central venous pressure, P(v-a)CO2 venous-to-arterial carbon dioxide partial pressure difference, VDI vasopressor dosing intensity = [norepinephrine (ug/min)] + [dopamine (ug/kg/min) /2] + [epinephrine (ug/min)] + [phenylephrine (ug/min) /10] + [血vasopressin (0.01 units/min) × 2].*p < 0.05